Sebastian Klobuch

Company: The Netherlands Cancer Institute

Job title: Medical Oncologist

Seminars:

BNT221: A First-in-Human Trial With a Personalised, Autologous Neoantigen-Specific T Cell Therapy in Metastatic Melanoma 5:15 pm

Understanding BNT221 Mechanism and Study Design – A personalized, neoantigenspecific autologous T cell therapy tested in a dose-finding study for advanced melanoma refractory to immune checkpoint blockade and BRAF-targeted therapy Navigating Safety and Tolerability – Well tolerated across doses with no severe toxicities; no cytokine release syndrome or neurotoxicity observed. Optimal dose range identified for…Read more

day: Day One